« Return to News | CROs/Service Providers

Covance Expands Sleep Study Expertise

Friday, September 4, 2009 11:14 AM

Covance is expanding its capacity to support specialized sleep studies through a collaboration with Sleep Medicine Associates. 

The collaboration gives Covance access to Sleep Medicine Associates’ clinical research facility and specialized support for studies targeting insomnia, restless leg syndrome, narcolepsy, fibromyalgia, and other conditions related to the central nervous system.

Under the terms of the partnership, board certified sleep expert David Cocanower, M.D., will provide specialized sleep and neurological monitoring services to the CRO, as well as provide consultation on sleep-specific protocols and study design. Sleep Medicine’s eight-bed research facility is located near Covance’s Evansville, Ill., clinical research unit.

“We are excited to expand our sleep therapeutic expertise, capacity, and recruitment capabilities to better support client needs in this highly specialized area,” said Randall Stoltz, M.D., CPI, medical director, Covance, in a statement.  “Sleep Medicine Associates adds industry-leading expertise and cutting edge technology to Covance’s portfolio of clinical development services.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.